Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8QXEY)

Drug Name

Evt201 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Sleep-wake disorder	7A00-7B2Z	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting GABA(A) receptor (GABAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PH94B NS	DMDC7OH	Social anxiety disorder	6B04	Phase 3	[3]
OV101	DMA6LR3	Angelman syndrome	LD90.0	Phase 3	[4]
Padsevonil	DMRZ1F2	Epilepsy	8A60-8A68	Phase 2/3	[5]
BTD-001	DMS6ZA0	Narcolepsy	7A20	Phase 2	[6]
SAGE-324	DM5NC39	Essential tremor or related tremors	8A04.1	Phase 2	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT00380003) Efficacy Study of EVT 201 to Treat Insomnia. U.S. National Institutes of Health.
2	The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients. Sleep Med. 2009 Sep;10(8):859-64.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study. Front Pharmacol. 2021 Oct 8;12:757825.
5	Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. J Pharmacol Exp Ther. 2020 Jan;372(1):11-20.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.